Market Place
Sourcing Support
MOMA Therapeutics Doses First Patient in Ph 1 Trial of MOMA-341
17 Jul 2025 //
BUSINESSWIRE
MOMA Therapeutics to Present Posters at AACR Annual Meeting 2025
17 Apr 2025 //
BUSINESSWIRE
MOMA Therapeutics Appoints Susan Pandya, M.D., to Board of Direct
01 Apr 2025 //
BUSINESSWIRE
Moma Therapeutics Licenses PARP1 Inhibitor Selectively
08 Jan 2025 //
BUSINESSWIRE
MOMA Therapeutics to Participate in Upcoming Investor Conferences
06 Nov 2024 //
BUSINESSWIRE
Bayer And MOMA Therapeutics Enter Oncology Collaboration
08 Oct 2024 //
BUSINESSWIRE
MOMA Starts Phase 1 Trial For MOMA-313 Polymerase Theta Helicase Inhibitor
19 Aug 2024 //
BUSINESSWIRE
MOMA appoints Marc Ballas as Head of Clinical Development
25 Jun 2024 //
BUSINESSWIRE
MOMA Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer
11 Mar 2024 //
BUSINESSWIRE
MOMA Therapeutics Announces Five-Year Discovery Collaboration with Roche
04 Jan 2024 //
BUSINESSWIRE
Roche pens third pact of the week in $66M upfront to MOMA Therapeutics
04 Jan 2024 //
ENDPTS
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.